CBAY CymaBay Therapeutics, Inc.

7.100.54 (+8.16%)
Close: June 18, 2019

7.140.05 (+0.63%)
Pre-market

Quote

Previous Close
$7.10
Day Range
$6.35-$7.35
52 Week Range
$4.82-$15.00
Volume
2,043,213
Avg Volume
1,851,110
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$487.40M
Enterprise Value (EV)
$252.75M
PE Ratio
-
EV/EBITDA
-3.49
Price/Sales
-
Price/Book
2.86
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-$105.00K
EBITDA
-$72.40M
EPS, ttm
-$1.31
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/5/2019 (47 days)
Debt to Equity
-
Debt
-
Cash
$178.66M
Net Debt
-

Performance

Beta
1.73
200 Day Moving Avg
$10.86
50 Day Moving Avg
$11.94
52 Week Change
-53.04%
YTD Change
-12.43%
1 Month Change
-47.01%
3 Month Change
-50.86%
6 Month Change
-12.77%
1 Year Change
-53.04%
2 Year Change
266.39%
5 Year Change
63.70%

Share Count

Shares Outstanding
68.7M
Float
59.4M
Restricted Shares
9.3M
Restricted Shares, %
13.57%

CymaBay Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Sujal Shah

Website: http://www.cymabay.com

Description: CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Employees: 43